
Edluar® is based on Orexo’s sublingual tablet technology and the active substance zolpidem. The product offers treatment for short-term insomnia. Zolpidem is a well-documented substance that has been used in the treatment of insomnia for a long time. The Edluar® tablet is placed under the tongue, where it rapidly dissolves and the active ingredient is absorbed through the mucous membrane.
Short facts | |
Technology | Edluar® |
Indication | Insomnia |
Commercial rights | Worldwide, Mylan |
Partner | Mylan |
Patent protection |
US until 2031, Europe until 2025 |
|
Edluar® was approved by the US Food and Drug Administration, FDA, in March 2009. In June 2012 Edluar® was approved for registration in Europe.